| Literature DB >> 32168810 |
Rafael Félix1,2, Patrícia Valentão2, Paula B Andrade2, Carina Félix1, Sara C Novais1, Marco F L Lemos1.
Abstract
Lipid peroxidation is a chemical reaction known to have negative impacts on living organisms' health and on consumer products' quality and safety. Therefore, it has been the subject of extensive scientific research concerning the possibilities to reduce it, both in vivo and in nonliving organic matrices. It can be started by a variety of oxidants, by both ROS-dependent and -independent pathways, all of them reviewed in this document. Another feature of this reaction is the capacity of lipid peroxyl radicals to react with the non-oxidized lipids, propagating the reaction even in the absence of an external trigger. Due to these specificities of lipid peroxidation, regular antioxidant strategies-although being helpful in controlling oxidative triggers-are not tailored to tackle this challenge. Thus, more suited antioxidant compounds or technologies are required and sought after by researchers, either in the fields of medicine and physiology, or in product development and biotechnology. Despite the existence of several laboratory procedures associated with the study of lipid peroxidation, a methodology to perform bioprospecting of natural products to prevent lipid peroxidation (a Lipid Peroxidation Inhibitory Potential assay, LPIP) is not yet well established. In this review, a critical look into the possibility of testing the capacity of natural products to inhibit lipid peroxidation is presented. In vitro systems used to peroxidize a lipid sample are also reviewed on the basis of lipid substrate origin, and, for each of them, procedural insights, oxidation initiation strategies, and lipid peroxidation extent monitoring are discussed.Entities:
Keywords: LPIP; bioactive compounds; in vitro; lipid peroxidation; natural products
Year: 2020 PMID: 32168810 PMCID: PMC7139815 DOI: 10.3390/antiox9030231
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Main molecules involved in the initiation and propagation of lipid peroxidation. LH: lipid molecule; LOO●: lipid peroxyl radical; L●: lipid radical; LOOH: lipid hydroperoxide.
Figure 2Main molecules involved in the termination of lipid peroxidation. RH: proton-donor; R●: radical.
Figure 3Schematic representation of lipid peroxidation initiators, according to their main features: ROS-mediated vs. ROS-independent mechanisms. PS—photosensitizer; oxTM—oxidized transition metal (Fe3+ or Cu2+). (a) Production of ROS (Superoxide Anion Radical, •O2–) by Iron (II) Fe2+ and Copper (I) Cu+; (b) Production of ROS (●O2–) by Light and Atmospheric Oxygen; (c) Production of ROS by Aerobic Metabolism; (d) Production of ROS (●OH) by Fenton Reaction (Reduced Metals and H2O2 Reaction); (e) Production of ROS (●OH) by Light and Hydrogen Peroxide; (f) Direct Oxidation by Light and a Photosensitizer (PS); (g) Direct oxidation by Iron(III) Fe3+ and Copper(II) Cu2+.
Figure 4Transition metals (iron and copper) redox recycling and its relevance in lipid peroxidation (LPO). AOx: Antioxidant.
Homogenization solutions, biomass-to-solvent percentages, and centrifugation conditions in the preparation of rat-derived substrates used in in vitro LPO models. Unless stated otherwise, the supernatant obtained in the differential centrifugation is the substrate used; ns—not stated; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
| Homogenization Solution | Biomass (% | Differential Centrifugation | Ref. |
|---|---|---|---|
| Rat liver homogenate | |||
| Tris-HCl buffer (40 mM, pH 7.4) | 25 | ns | [ |
| Phosphate buffer (50 mM, pH 7.4) with KCl 120 mM | 10 | 700× | [ |
| Tris-HCl buffer (100 mM, pH 7.4) | 10 | 1400× | [ |
| Phosphate buffer (50 mM, pH 7.4) | 20 | 800× | [ |
| Phosphate buffer (100 mM, pH 7.4) with KCl 150 mM | 10 | 800× | [ |
| HEPES buffer (100 mM, pH 7.2) with KCl 125 mM | 25 | 400 rpm/15 min | [ |
| Tris-HCl buffer (10 mM, pH 7.4) | 10 | 3600× | [ |
| Rat brain homogenate | |||
| Phosphate buffer (50 mM, pH 7.4) | 20 | 800× | [ |
| Tris-HCl (10 mM, pH 7.4) | 10 | 3000× | [ |
| Tris-HCl (10 mM, pH 7.4) | 10 | 4000× | [ |
| Tris-HCl (100 mM, pH 7.4) | 10 | 1400× | [ |
| KCl 1.15% ( | 10 | 5000× | [ |
| Phosphate buffer (50 mM, pH 7.4) | 10 | 10,000× | [ |
| Tris-HCl (10 mM, pH 7.4) | 20 | 3600× | [ |
| Saline solution | 10 | 3000× | [ |
| Phosphate buffer (10 mM, pH 7.4) | 14 | 10,000× | [ |
| Rat liver mitochondria | |||
| Tris-KCl (-) | 10 | 2160 rpm/15 min—discard pellet | [ |
| HEPES buffer (10 mM, pH 7.4) w/ Sucrose 25 mM and Protease Inhibitor Cocktail, 0.5% ( | ns | 1000× | [ |
| Rat liver microsomes | |||
| Tris-malate buffer (5 mM, pH 7.4) with KCl 1.15% ( | ns | 15,000× | [ |
| Tris-HCl (50 mM, pH 7.4) with KCl 150 mM | ns | 10,000× | [ |
| HEPES buffer (10 mM, pH 7.4) w/Sucrose, 25 mM and Protease Inhibitor Cocktail, 0.5% ( | ns | 1000× | [ |
Overview of assay conditions used in models with rat-derivatives as substrate. Unless otherwise stated, TBARS were measured at the mentioned endpoints. NP—natural product; ns—not stated; AscH2—ascorbic acid; SNP—sodium nitroprusside; AscH–—ascorbate anion; G6P—glucose-6-phosphate; G6Pdhase—G6P dehydrogenase; ADP: adenosine diphosphate; t-BOOH: tert-butylhydroperoxide; NADPH: reduced nicotinamide adenine dinucleotide phosphate; DMSO: dimethyl sulfoxide; TBARS: thiobarbituric acid Reactive Species.
| Substrate | Oxidative Trigger | Concentration | NP Inclusion | Incubation-Detection System | Ref. | |
|---|---|---|---|---|---|---|
| Type | Concentration | Type | ||||
| Rat liver homogenate | 5% ( | Fe2+/AscH2 | 0.16 mM/0.06 mM | ns | TBARS (1 h at 37 °C) | [ |
| 3.3% ( | Fe3+/ADP/AscH2 | 0.1 mM/1.7 mM/0.5 mM | ns | TBARS (1 h at 37 °C) | [ | |
| 10 mg protein/mL | none (O2) | ns | Dissolved in water or DMSO | TBARS (15 min at 37 °C) | [ | |
| 0.5 mg protein/mL | t-BOOH | 3 mM | Dissolved in water or DMSO | Chemiluminescence measured online over time, at 30 °C | [ | |
| 3.3% ( | Fe2+/SNP | ns | ns | TBARS (1 h at 37 °C) | [ | |
| 2.5% ( | Fe3+ | 10 µM | 5% ( | TBARS (30 min at 37 °C) | [ | |
| ns | Fe3+/citrate/AscH− | ns | ns | TBARS (ns) | [ | |
| ns | Fe2+ | 10 µM | ns | TBARS (1 h at 37 °C) | [ | |
| Rat liver mitochondria | 1 mg protein/mL | Fe2+/AscH2 | 10 mM/200 mM | ns | TBARS (20 min at 37 °C) | [ |
| 0.87% ( | Fe2+/AscH2 | 1.3 mM/4.3 µM | ns | TBARS (1 h at 37 °C) | [ | |
| Rat liver microsomes | 0.2 mg protein/mL | Fe2+/AscH2/ADP | 1.2 µM/5 µM/0.4 mM | 0.1% ( | HPLC-TBARS along time, 30 °C | [ |
| 0.2 mg protein/mL | Fe2+/NADPH | 5 nM/60 µM | 4% ( | TBARS (30 min at 37 °C) | [ | |
| 0.25 mg protein/mL | (post heat-inactivation) | 1 µM/50 µM/40 µM | ns | TBARS (15 min at 37 °C) | [ | |
| 0.25 mg protein/mL | NADP/G6P/G6Pdhase | 0.2 mM/3 mM/1 U | ns | TBARS (15 min at 37 °C) | [ | |
| 0.25 mg protein/mL | Fe2+/AscH– | 2.5 µM/0.5 mM | 5% ( | TBARS (30 min at 37 °C) | [ | |
| Rat brain homogenate | ns | Fe2+ | 10 µM | ns | TBARS (1 h at 37 °C) | [ |
| 3.3% ( | Fe2+/SNP | ns | ns | TBARS (1 h at 37 °C) | [ | |
| 15% ( | Fe2+ | 0.4 mM | ns | TBARS (45 min at 37 °C) | [ | |
| ns | SNP | 7 mM | ns | TBARS (1 h at 37 °C) | [ | |
| 0.9% ( | Fe3+/H2O2 | 0.3 mM/60 µM | 8.6% ( | TBARS (1 h at 37 °C) | [ | |
| 3.1% ( | Fe3+/H2O2 | 12.5 µM/3.1 µM | ns | TBARS (30 min at 37 °C) | [ | |
| 10% ( | SNP | 5 µM | ns | TBARS (1 h at 37 °C) | [ | |
| 10% ( | Fe2+ | 10 µM | ns | TBARS (1 h at 37 °C) | [ | |
| 10% ( | Quinolinic acid | 1 mM | ns | TBARS (1 h at 37 °C) | [ | |
| 10% ( | SNP | 5 µM | ns | TBARS (1 h at 37 °C) | [ | |
| 10% ( | none (O2) | ns | 50% ( | TBARS (40 min at 37 °C) | [ | |
Overview of assay conditions used in models with low-density lipoprotein as substrate; ns—not stated; CD—conjugated dienes.
| Oxidation Trigger | LDL Concentration | Incubation and Detection | Ref. | |
|---|---|---|---|---|
| Type | Concentration | |||
| Cu2+ | 1.66 µM | 0.25 mg/mL | CD, TBARS and iodometry along time (Room Temperature) | [ |
| 10 µM | 50 μg protein/mL | CD along time (37 °C); TBARS (2 h at 37 °C) | [ | |
| 3 µM | 100 μg protein/mL | TBARS and electrophoretic mobility after 6 and 24 h at 37 °C | [ | |
| 5 µM | 0.3 mM cholesterol | CD along time; TBARS and electrophoretic mobility after 4 and 24 h at 37 °C | [ | |
| ns | 0.08 mg cholesterol/mL | CD along time at 30 °C | [ | |
| ns | 1 mg protein/mL | TBARS after overnight at 37 °C | [ | |
| 1 mM | 150 ug/mL | CD along time at 37 °C | [ | |
| 20 mM | 150 ug/mL | TBARS after 3 h at 37 °C | [ | |
| 5 µM | 100 μg protein/mL | TBARS after 90 min at 37 °C | [ | |
| 5 µM | 0.1 uM | CD along time at 37 °C | [ | |
| 0.1 mM | 200 μg protein/mL | CD along time at 37 °C | [ | |
| Cu2+/H2O2 | 40 µM/80 µM | 3.15 mg protein/mL | Electrophoretic mobility after 3 h at 37 °C | [ |
| AAPH | 4 mM | 0.3 mM cholesterol | CD along time; TBARS and electrophoretic mobility after 4 and 24 h at 37 °C | [ |
| 5 mM | 200 μg protein/mL | Cholesteryl esters hydroperoxides quantification by HPLC-UV along time at 37 °C | [ | |
Approaches to the dispersion of linoleic acid in an aqueous media. LA—linoleic acid; PB—phosphate buffer; NP—natural product.
| Main Solvent in Reactional Medium | Method of Dispersion | Ref. |
|---|---|---|
| Water | Emulsification of LA in PB 20 mM pH 7, using Tween-20 (5.6 µg/mL LA and 5.6 µg/mL Tween-20) | [ |
| Dissolution of LA (8 mM) in Borate buffer 50 mM pH 9 | [ | |
| Dissolution of sodium linoleate in water (16 mM) | [ | |
| Dissolution of LA in ethanol, 2.5% ( | [ | |
| Ethanol | Dissolution of LA (1.3% ( | [ |
Overview of assay conditions used in models with liposomes as substrate. PL—polar lipid; ns—not stated; AscH−—ascorbate anion; AscH2—ascorbic acid; NP—natural product; CD—conjugated dienes; PL-OOH—phospholipid hydroperoxides.
| Substrate Preparation | Substrate Concentration (mg/mL) | Oxidative Trigger | Incubation and Detection | Ref. | ||
|---|---|---|---|---|---|---|
| Polar Lipid | Liposome Generation | Type | Concentration | |||
| Mix of Bovine Brain Phospholipids | PL in CCl3 (1 mg/mL) | 0.3 | Cu2+ | 5 µM | Endpoint measurement by TBARS and fatty acid profiling after 24 h at 37 °C w/ atm O2 and light | [ |
| Soya Bean Lecithin | Suspension of PL in water (8 mg/mL) | 7.9 | Cu2+ | 20 µM | CD and TBARS over time at 31 °C with agitation | [ |
| Lecithin | PL in CCl3:Meth-nol 86:14 (10 mg/mL) | 3.6 | AAPH | 10 mM | Endpoint measurement by TBARS after 2 h at 37 °C | [ |
| Soybean Phosphatidyl-choline | PL in CCl3 (10 mg/mL) | 0.1 | Fe3+/AscH− | 50 µM/100 µM | Endpoint measurement by TBARS after 1h at 37 °C | [ |
| Egg yolk phospholipids | PL in CCl3 (2.5 mg/mL) + sample in methanol | 0.625 | Light | ns | CD along time at 50 °C | [ |
| Egg yolk phospholipids | PL in CCl3 (2.5 mg/mL) + sample in methanol | 0.625 | Light + Singlet Oxygen | ns | CD along time at 50 °C | [ |
| Egg lecithin | PL in PB (10 mM pH 7.4) (10 mg/mL) | 9.5 | Fe3+/AscH2 | 6.3 µM/6.3 µM | Endpoint measurement by TBARS after 1 h at 37 °C | [ |
| Egg phosphati-dilcholine | PL and sample in CCl3:Metha-nol | ns | AAPH | 0.5 mM | PL-OOH along time by HPLC-UV | [ |